Actively Recruiting
Radiation Therapy Targeting Metastatic Sites in Children and Young Adults With Soft Tissue and Bone Sarcoma
Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2026-07-13
70
Participants Needed
3
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to improve overall survival for children, adolescents, and young adults with metastatic soft tissue and bone sarcoma by targeting metastatic sites with radiation therapy. The study focuses on consolidative radiation therapy cRT after standard chemotherapy in this population, addressing gaps left by prior adult-focused studies. It also explores circulating tumor DNA as a potential biomarker to track response and provide additional prognostic information. Participants are assigned to one of two groups Stratum A, which receives standard chemotherapy followed by consolidative radiation to the primary tumor and all metastatic sites, and Stratum B, which receives standard second-line systemic therapy with radiation to at least one metastatic site. The study is a single-arm, non-randomized phase II trial designed to enroll 32 evaluable patients under age 39. During the study, participants undergo standard chemotherapy and restaging imaging before radiation treatment. Researchers will monitor event-free survival and overall survival over two years to evaluate the impact of consolidative radiation. Feasibility of tracking circulating tumor DNA throughout treatment will also be assessed. The trial includes ongoing evaluations of disease progression, imaging, and survival outcomes over the study period ending in 2030.
CONDITIONS
Brief Title
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Research Team
S
Sahaja Acharya, MD
C
Colette Youstra, MSPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here